Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns ...

Chronic conditions “are widespread yet remain invisible” with many people living with long-term disorders “masking” their ...

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Swiss CDMO Lonza is making a move to strengthen and speed up quality control testing with the purchase of French rapid ...

The biotech has a deck of RASP modulators. As Aldeyra has accrued evidence in a range of indications, management has shuffled the pack by changing its priority assets in specific diseases. The company ...

The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while ...

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

Qureator Organ-on-Chip Breakthrough Marks Milestone Under FDA Modernization Act 2.0 | FDA approves IND based on human ...